We report a case of non-immune hydrops fetalis (NIHF) caused by herpes simplex virus type 2 (HSV-2) in an infant whose mother had recurrent HSV-2 infection. In spite of prematurity, severe disseminated infection and hydrops, the infant survived and was neurologically intact. HSV-2-induced NIHF is extremely rare, particularly in the setting of recurrent maternal infection, and this case is, to our knowledge, the first report of a surviving infant. HSV-2 should be considered in the differential diagnosis of NIHF and early initiation of empiric acyclovir therapy is recommended in this setting, pending the results of virologic diagnostic tests.
INTRODUCTION
Non-immune hydrops fetalis (NIHF), which occurs in 1 in 2500 to 4000 pregnancies, continues to have a very high perinatal mortality rate, ranging from 50 to 90%. 1, 2 Cardiac disorders, genetic abnormalities, fetal malformations, hematologic disorders and infections can all lead to NIHF. Among the infectious etiologies of NIHF, the most common causes are cytomegalovirus, toxoplasmosis, syphilis and parvovirus B19 infection. Herpes simplex virus (HSV) is only rarely described as a cause of NIHF, typically in the setting of primary maternal infection, and no surviving infants have been described in the previous case reports. [3] [4] [5] [6] [7] [8] [9] [10] We report the case of an infant with NIHF secondary to intrauterine HSV-type 2 (HSV-2) infection who survived; notably, this infant was born to a woman with recurrent HSV-2 infection.
CASE
A 24-year-old gravida 1 para 0 woman presented at 27-1/7 weeks' gestation with preterm labor and spontaneous rupture of membranes for 2 h. Her pregnancy had been uncomplicated to that point, with normal ultrasounds at 12 and 20 weeks. Prenatal labs were unremarkable and she was HIV negative. The patient had a history of a primary genital HSV-2 infection approximately 4 years prior to this pregnancy, documented at that time by culture and type-specific serology (HSV-2 immunoglobulin G positive). She denied a history of symptomatic recurrent genital HSV infections, and she had not received suppressive nucleoside therapy prior to or during this pregnancy. At presentation, she was fully dilated, and a hydropic-appearing male infant was spontaneously delivered several minutes after admission. The infant had no spontaneous respiratory effort or movement, with an initial heart rate less than 60. Resuscitation included intubation, positive pressure ventilation, chest compressions, intravenous epinephrine and intravenous fluids. Surfactant was administered. Apgar scores were 4 and 7 at 1 and 5 min, respectively.
Following transfer to our neonatal intensive care unit from a referring facility on day of life (DOL) 1, examination was remarkable for a severely hydropic-appearing premature infant with a distended abdomen and an enlarged, firm liver. Skin examination showed diffuse erythema, non-tense bullae on the chest and extremities, as well as superficial erosions and hemorrhagic macules and papules. The face and scalp were notably spared ( Figure 1 , respectively. The infant required high-frequency oscillatory ventilation for severe hypoxemic respiratory failure. Initial echocardiogram showed evidence of pulmonary hypertension with tricuspid regurgitation and right-to-left shunting through the patent foramen ovale and patent ductus arteriosus, as well as severely depressed biventricular function and a small pericardial effusion without tamponade. Inhaled nitric oxide (iNO) was initiated, resulting in a change of the patent ductus arteriosus shunt to bidirectional status, and subsequent clinical improvement was noted. Although iNO therapy is not routinely recommended for severe respiratory failure and has not been shown to be beneficial in this setting, 11, 12 a recently published NIH consensus statement on iNO therapy for premature infants (http://consensus.nih.gov/ 2010/inofinalstatement.htm) noted that there are clinical situations, including pulmonary hypertension, in which iNO may have benefit in preterm infants. Given the clinical presentation and the echocardiogram results, we felt that iNO would be beneficial to this infant. Medical therapies included empiric ampicillin and gentamicin, and pressor support (dopamine, 3 to 20 mcg kg À 1 min
, for 3 days with peak dosing at approximately 48 h of life, and dobutamine 3 to 7 mcg kg À 1 min À 1 , for 12 h on DOL 2). Corticosteroid therapy for clinical adrenal insufficiency was initiated on DOL 3 (hydrocortisone sodium succinate, 4 mg À 1 kg À 1 day for 2 days, which was tapered over the following 5 days). Intravenous immunoglobulin (2 doses of 0.5 g kg À 1 each on DOL 3 and 4), and multiple packed red blood cell, platelets, and fresh frozen plasma transfusions were also administered. Empiric acyclovir therapy was initiated at 8 h of life. Abdominal ultrasound demonstrated diffuse hepatic microcalcifications. Head ultrasound revealed hemorrhage in the left ventricle without ventricular dilation with a small periventricular hemorrhage, as well as right germinal matrix hemorrhage.
Diagnostic studies obtained to elucidate the potential etiology of NIHF included parvovirus, toxoplasma and treponema serologies; blood and urine cytomegalovirus culture and polymerase chain reaction (PCR); and blood PCR for HIV and enterovirus, all of which were negative. The total serum immunoglobulin M level was 234 mg dl
. Blood HSV-2 PCR was positive; in addition, HSV-2 was also identified by both conjunctival viral culture and PCR, and from the nasopharynx and rectum by PCR. Ophthalmologic exam revealed bilateral herpetic keratitis. A lumbar puncture was not possible due to clinical instability. Placental pathology demonstrated viral cytopathic changes in amniotic epithelial cells of the fetal membranes, including chromatin margination and eosinophilic intranuclear inclusions. Immunohistochemical staining with an HSV-specific monoclonal antibody confirmed the presence of HSV (Figure 2 ). There was also evidence of acute and chronic funisitis and acute chorioamnionitis, but no villitis.
HSV DNA was no longer detected in blood by DOL 10. The infant was treated with high-dose intravenous acyclovir (40 mg kg À 1 per day) for 30 days and then transitioned to oral acyclovir suppressive therapy (300 mg m À 2 three times per day) for 6 months. 13 Topical trifluridine was also administered for herpetic keratitis and was continued until this resolved. The skin lesions resolved, although post-inflammatory hypopigmentation was noted. Brain MRI prior to discharge showed moderate atrophy of the right cerebellar hemisphere and slightly less than expected T1 hyperintensity in the corticospinal tracts and posterior limb of the internal capsule on the left. There were no cystic changes. The infant was discharged on DOL 114 at 43-2/7 weeks corrected age with a plan to continue supplemental low-flow oxygen therapy and gastrostomy tube feeds. Oxygen therapy was gradually weaned and discontinued by 6 weeks post-discharge.
Upon discontinuation of acyclovir, after 6 months of suppressive therapy, the patient had recurrence of skin lesions. He was again treated with intravenous acyclovir for 48 h, and transitioned to oral suppressive therapy for an additional 3 months, with prompt resolution of his lesions. Neurodevelopmental outcome at 12 months corrected gestational age was performed using the Bayley Scales of Infant Development -Third Edition, a comprehensive measure of general intellectual ability that provides separate scores for cognitive, language and motor domains. This evaluation demonstrated that his cognitive function was within the average range, and that he had only minimal-to-mild motor and language delays. His cognitive composite score was 90 ( ± 1 s.d. ¼ 85 to 115) with an age equivalent of 10 months. The overall language composite score was 79 (±1 s.d. ¼ 85 to 115). Finally, he performed at the 10-month age equivalency on the measure of fine motor ability. His gross motor skills, including locomotion, coordination, balance and motor planning, were within the 9-month age equivalency with an overall motor composite score of 82 (± 1 s.d. ¼ 85 to 115). DISCUSSION NIHF due to congenital HSV infection has only rarely been reported. [3] [4] [5] [6] [7] [8] [9] [10] Our review of the literature identified only five cases of frank hydrops caused by HSV (Table 1 ). This case, to our knowledge, is the first reported case of survival of an infant with HSV-induced NIHF. Moreover, our case is unique insofar as it occurred in the context of recurrent maternal HSV-2 infection.
Most neonatal HSV infections result from exposure to the virus in the genital tract during delivery.
14 It is estimated that intrauterine infection occurs in only 4 to 5% of neonatal HSV cases. 15, 16 Additionally, in the largest and most recent review on intrauterine HSV infection, only 6 of 64 reported infants presented with hydrops. 15 Intrauterine infection can occur as a consequence of transplacental or ascending infection. Evidence of HSV found in the amniotic epithelium of the fetal membranes without villitis (Figure 2 ) suggests ascending and not transplacental transmission in this case. Although ascending infection without rupture of membranes is uncommon, this mode of transmission has been reported previously with placental pathology similar to the present case. [16] [17] [18] [19] In the aforementioned cases, primary genital HSV infection was proven or presumed based on maternal history. Interestingly, the mother in our case had long-established disease, with documented genital HSV-2 infection 4 years prior to this pregnancy. The vast majority of cases of neonatal HSV infection occur in the setting of primary maternal infection during pregnancy. The reduced risk of neonatal HSV in the setting of recurrent maternal infection is believed to be related to transplacental transfer of antibodies mitigating the transmission of infection.
14 Although congenital HSV and NIHF in our patient in the setting of documented recurrent maternal infection was unexpected, the infant survived and had a good long-term neurologic outcome. Although a large proportion of maternal immunoglobulin G antibodies transfer to the fetus during the third trimester of pregnancy, maternal immunoglobulin G can reach the fetus as early as 17 weeks' gestation. 20 With a presumed recurrent HSV-2 infection in pregnancy leading to the baby's presentation, the mother may have high levels of HSV-2-specific antibodies that protected this infant despite his premature birth. The absence of data on maternal and neonatal HSV-2 antibody levels in this case makes this theory speculative, but may help explain the good outcome. In addition, the prompt administration of high-dose acyclovir (started within 8 h of birth) likely contributed to this infant's survival. The role of cell-mediated immunity in resolution of neonatal HSV infection is poorly understood, 21 as is the role of the interferon response. 22 Infants with genetic polymorphisms in the toll-like receptor 3 gene are predisposed to more severe neonatal HSV infections, 23 but unfortunately TLR3 polymorphism analysis was not available for the infant described in this case.
In conclusion, although a rare cause of NIHF, HSV infection should always be considered in the differential diagnosis, even in the setting of a maternal history of recurrent HSV. Empiric early treatment with acyclovir should be initiated in a neonate with NIHF of unknown etiology while awaiting diagnostic studies, as this may significantly improve the chance of survival.
